Skip to main content
TipRanks
Go Ultimate75% OFF

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

23 Followers
See the Price Targets and Ratings of:

VX1 Analyst Ratings

Strong Buy
22Ratings
20Buy2Hold0Sell
Based on 22 analysts giving stock ratings to Vertex Pharmaceuticals in the past 3 months

VX1 Stock 12 Month Forecast

€552.92▲(13.49% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is EUR 552.92 with a high forecast of EUR 653.36 and a low forecast of EUR 398.32. The average price target represents a 13.49% change from the last price of EUR 487.20.
Highest Price Target€653.36Average Price Target€552.92Lowest Price Target€398.32

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:VX1
Price TargetArticle
Bank of America Securities―buy―Reiterated11/12/26
UBS€554.23→€576.75buy18.38%UpsideReiterated11/04/26
H.C. Wainwright€577.66buy18.57%UpsideReiterated11/04/26
Barclays€556.03→€564.14buy15.79%UpsideReiterated11/04/26
Maxim Group€518.18→€558.73buy14.68%UpsideReiterated11/04/26
Citi€527.19buy8.21%UpsideReiterated11/03/26
J.P. Morgan€504.66→€513.67buy5.43%UpsideAssigned11/03/26
Goldman Sachs€589.37→€653.36buy34.10%UpsideAssigned11/03/26
Morgan Stanley€599.28→€594.78buy22.08%UpsideAssigned11/03/26
Stifel Nicolaus€450.59→€507.36hold4.14%UpsideReiterated11/03/26
Scotiabank€594.78buy22.08%UpsideAssigned11/03/26
TD Cowen€495.65→€518.18buy6.36%UpsideReiterated11/03/26
BMO Capital€540.71→€558.73buy14.68%UpsideReiterated11/03/26
Wells Fargo€495.65→€585.77buy20.23%UpsideReiterated11/02/26
Cantor Fitzgerald€536.20→€557.83buy14.50%UpsideReiterated11/02/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
QUITAchieve Life Sciences
COGTCogent Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Naz Rahman
Naz RahmanMaxim Group
Success Rate14/16 ratings generated profit
88%
Average Return
+8.28%

Copying Naz Rahman's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +8.28% per trade.

1 Year
Naz Rahman
Naz RahmanMaxim Group
Success Rate15/16 ratings generated profit
94%
Average Return
+18.51%

Copying Naz Rahman's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +18.51% per trade.

2 Years
Success Rate39/40 ratings generated profit
98%
Average Return
+24.79%

Copying Geoff Meacham's trades and holding each position for 2 Years would result in 97.50% of your transactions generating a profit, with an average return of +24.79% per trade.

VX1 Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for VX1
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00000
Buy5059706253
Hold99963
Sell11100
Strong Sell00000
total6069806856

In the current month, VX1 has received 53 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 552.92.

VX1 Financial Forecast

€2€2.75€3.5€4.25€5Q1 2026Q3 2026Q4 2026
High€4.90
Consensus€3.81
Low€3.44

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is EUR 3.81 with a range of EUR 3.44 to EUR 4.90. The previous quarter’s EPS was EUR 4.32. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€2.7B€2.9B€3B€3.1B€3.3BQ1 2026Q3 2026Q4 2026
High€3.26B
Consensus€3.17B
Low€3.1B

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is EUR 3.17B with a range of EUR 3.10B to EUR 3.26B. The previous quarter’s sales results were EUR 3.12B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is €552.92.
What is DE:VX1’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 13.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Vertex Pharmaceuticals a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s share price target?
The average share price target for Vertex Pharmaceuticals is €552.92. This is based on 22 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €653.36, and the lowest forecast is €398.32. The average share price target represents a 13.49% increase from the current price of €487.2.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Street analysts.
How can I buy shares of Vertex Pharmaceuticals?
To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.